CDKN2AIP: A Potential Drug Target and Biomarker for Cancer (G55602)

Target Name: CDKN2AIP

NCBI ID: G55602

CDKN2AIP

CDKN2AIP: A Potential Drug Target and Biomarker for Cancer

CDKN2AIP (CDKN2A-interacting protein) is a gene that encodes a protein that is involved in various cellular processes. The protein has been identified as a potential drug target and biomarker for cancer due to its unique structure and the involvement of various signaling pathways. In this article, we will discuss the CDKN2AIP protein, its functions, potential drug targets, and its potential as a biomarker for cancer.

Structure and Functions

CDKN2AIP is a 21-kDa protein that is expressed in various tissues, including breast, ovarian, and prostate cells. The protein has a unique structure that consists of a 194 amino acid residue protein tail and a 31 amino acid residue N-terminal transmembrane region. The protein has been shown to interact with various intracellular signaling pathways, including TGF-β, NF-kappa-B, and AP-1.

One of the unique features of CDKN2AIP is its ability to interact with the transcription factor CDKN2A. CDKN2A is a key regulator of the TGF-β pathway and has been shown to play a role in various cellular processes, including cell growth, differentiation, and apoptosis. The interaction between CDKN2AIP and CDKN2A has been shown to regulate various cellular processes, including cell growth, apoptosis, and angiogenesis.

CDKN2AIP has also been shown to interact with various signaling pathways, including the TGF-β pathway, NF-kappa-B pathway, and AP-1 signaling pathway. The TGF-β pathway is involved in cell growth, differentiation, and apoptosis, and has been shown to play a role in the development and progression of various diseases, including cancer. The NF-kappa-B pathway is involved in inflammation and immune responses, and has been shown to play a role in the development of various diseases, including cancer. The AP-1 signaling pathway is involved in cell growth and differentiation, and has been shown to play a role in the development and progression of various diseases, including cancer.

Potential Drug Targets

CDKN2AIP has been identified as a potential drug target due to its unique structure and the involvement of various signaling pathways. One of the primary drug targets for CDKN2AIP is the TGF-β pathway. The TGF-β pathway is involved in cell growth, differentiation, and apoptosis, and has been shown to play a role in the development and progression of various diseases, including cancer.

There are several small molecules that have been shown to interact with CDKN2AIP and have the potential to be drug candidates for cancer. One of the most promising small molecules is inhibitor of the TGF-β pathway, which has been shown to have anti-tumor effects. Another small molecule that has been shown to interact with CDKN2AIP is a specific inhibitor of the NF-kappa-B pathway, which has been shown to have anti-inflammatory effects and may be a potential cancer therapeutic.

Potential Biomarkers

CDKN2AIP has also been shown to be a potential biomarker for cancer due to its unique structure and the involvement of various signaling pathways. One of the primary biomarkers for cancer is the expression of various genes that have been altered in cancer cells. The expression of CDKN2AIP has been shown to be altered in various breast and ovarian cancers, and has been shown to be associated with poor prognosis in these cancers.

Another potential biomarker for cancer is the expression of various genes that have been altered in cancer cells

Protein Name: CDKN2A Interacting Protein

Functions: Regulates DNA damage response in a dose-dependent manner through a number of signaling pathways involved in cell proliferation, apoptosis and senescence

The "CDKN2AIP Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CDKN2AIP comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets